skip-to-main

Spikevax bivalent Original/Omicron BA.4-5 (50 micrograms/50 micrograms)/mL dispersion for injection

Emergency Use Authorization (EUA) has been granted in Qatar for Spikevax bivalent Original/Omicron BA.4-5 for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Spikevax bivalent Original/Omicron BA.1 (50 micrograms/50 micrograms)/mL dispersion for injection

Emergency Use Authorization (EUA) has been granted in Qatar for Spikevax bivalent Original/Omicron BA.1 for active immunisation to prevent COVID‑19 caused by SARS-CoV-2 in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID‑19.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Spikevax (Previously COVID-19 Vaccine Moderna)

Emergency Use Authorization has been granted in Qatar for Spikevax (COVID-19 Vaccine Moderna) to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Tools

Temperature Excursion Tool

Temperature Excursion Tool

See what to do with vials of the Moderna COVID-19 Vaccine that may have experienced a temperature excursion prior to administering.

Contact Moderna

8am-5pm AST – Sun - Thr
EMEAMedinfo@modernatx.com

    © 2023 Moderna, Inc.

    QA-COV-2100001 09/2022